Literature DB >> 11748184

Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium.

Biswajit Biswas1, Sankar Adhya, Paul Washart, Brian Paul, Andrei N Trostel, Bradford Powell, Richard Carlton, Carl R Merril.   

Abstract

Colonization of the gastrointestinal tract with vancomycin-resistant Enterococcus faecium (VRE) has become endemic in many hospitals and nursing homes in the United States. Such colonization predisposes the individual to VRE bacteremia and/or endocarditis, and immunocompromised patients are at particular risk for these conditions. The emergence of antibiotic-resistant bacterial strains requires the exploration of alternative antibacterial therapies, which led our group to study the ability of bacterial viruses (bacteriophages, or phages) to rescue mice with VRE bacteremia. The phage strain used in this study has lytic activity against a wide range of clinical isolates of VRE. One of these VRE strains was used to induce bacteremia in mice by intraperitoneal (i.p.) injection of 10(9) CFU. The resulting bacteremia was fatal within 48 h. A single i.p. injection of 3 x 10(8) PFU of the phage strain, administered 45 min after the bacterial challenge, was sufficient to rescue 100% of the animals. Even when treatment was delayed to the point where all animals were moribund, approximately 50% of them were rescued by a single injection of this phage preparation. The ability of this phage to rescue bacteremic mice was demonstrated to be due to the functional capabilities of the phage and not to a nonspecific immune effect. The rescue of bacteremic mice could be effected only by phage strains able to grow in vitro on the bacterial host used to infect the animals, and when such strains are heat inactivated they lose their ability to rescue the infected mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748184      PMCID: PMC127648          DOI: 10.1128/IAI.70.1.204-210.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

Review 1.  Phage therapy: past history and future prospects.

Authors:  R M Carlton
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1999       Impact factor: 4.291

Review 2.  Vancomycin-resistant enterococcal infections.

Authors:  B E Murray
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

3.  Phage therapy--advantages over antibiotics?

Authors:  A Pirisi
Journal:  Lancet       Date:  2000-10-21       Impact factor: 79.321

4.  Fate of bacteriophage lambda in non-immune germ-free mice.

Authors:  M R Geier; M E Trigg; C R Merril
Journal:  Nature       Date:  1973-11-23       Impact factor: 49.962

5.  Vancomycin-resistant enterococci.

Authors:  A H Uttley; C H Collins; J Naidoo; R C George
Journal:  Lancet       Date:  1988 Jan 2-9       Impact factor: 79.321

6.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

7.  Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics.

Authors:  H W Smith; M B Huggins
Journal:  J Gen Microbiol       Date:  1982-02

Review 8.  Bacteriophages show promise as antimicrobial agents.

Authors:  J Alisky; K Iczkowski; A Rapoport; N Troitsky
Journal:  J Infect       Date:  1998-01       Impact factor: 6.072

9.  Treatment of experimental infections of mice with bacteriophages.

Authors:  J S Soothill
Journal:  J Med Microbiol       Date:  1992-10       Impact factor: 2.472

10.  Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa.

Authors:  J S Soothill
Journal:  Burns       Date:  1994-06       Impact factor: 2.744

View more
  136 in total

1.  Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections.

Authors:  Caroline Westwater; Laura M Kasman; David A Schofield; Phillip A Werner; Joseph W Dolan; Michael G Schmidt; James S Norris
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Impact of relative humidity and collection media on mycobacteriophage D29 aerosol.

Authors:  Keyang Liu; Zhanbo Wen; Na Li; Wenhui Yang; Jie Wang; Lingfei Hu; Xiaokai Dong; Jianchun Lu; Jinsong Li
Journal:  Appl Environ Microbiol       Date:  2011-12-22       Impact factor: 4.792

3.  Isolation and characterization of a novel bacteriophage φ4D lytic against Enterococcus faecalis strains.

Authors:  Sylwia Parasion; Magdalena Kwiatek; Lidia Mizak; Romuald Gryko; Michał Bartoszcze; Janusz Kocik
Journal:  Curr Microbiol       Date:  2012-06-06       Impact factor: 2.188

4.  Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments.

Authors:  A Vieira; Y J Silva; A Cunha; N C M Gomes; H-W Ackermann; A Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-10       Impact factor: 3.267

5.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Authors:  Ryohei Watanabe; Tetsuya Matsumoto; Go Sano; Yoshikazu Ishii; Kazuhiro Tateda; Yoshinobu Sumiyama; Jumpei Uchiyama; Shingo Sakurai; Shigenobu Matsuzaki; Shosuke Imai; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

7.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

8.  Compensatory fetal membrane mechanisms between biglycan and decorin in inflammation.

Authors:  Luciana Batalha de Miranda de Araujo; Casie E Horgan; Abraham Aron; Renato V Iozzo; Beatrice E Lechner
Journal:  Mol Reprod Dev       Date:  2015-04-23       Impact factor: 2.609

9.  Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model.

Authors:  Susan M Lehman; Rodney M Donlan
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

10.  In silico and in vivo evaluation of bacteriophage phiEF24C, a candidate for treatment of Enterococcus faecalis infections.

Authors:  Jumpei Uchiyama; Mohammad Rashel; Iyo Takemura; Hiroshi Wakiguchi; Shigenobu Matsuzaki
Journal:  Appl Environ Microbiol       Date:  2008-05-02       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.